1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

RESULTS FOR THE YEAR ENDED 31ST MARCH, 2012

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2012

  (Rupees in '000')
    Un -audited  Audited
S. No. Particulars Quarter ended Year Ended Year Ended
    31.03.2012 31.12.2011 31.03.2011 31.03.2012 31.03.2011
PART-I          
1 (a) Income from Operation        
    Gross Sales
13,225
17,496
10,838
70,455
60,337
    Less: Excise Duty
1,509
1,000
1,156
4,435
3,313
      Net Sales
11,716
16,496
9,682
66,020
57,024
  (b) Other Operating Income 
-
-
-
-
-
  Total Income from Operation
11,716
16,496
9,682
66,020
57,024
2 Expenditure
-
-
-
-
-
  (a) Consumption of Materials
6,761
4,587
3,754
24,418
21,033
  (b) Purchase of Goods Traded
937
483
-
3,457
3,045
  (c) (Increase)/Decrease in stock in trade
-5,021
1,473
-2,133
-1,095
-2,311
  (d) Staff Cost
4,610
6,314
4,175
22,545
19,048
  (e) Depreciation
666
644
650
2,599
2,578
  (f) Other Expenditure
3,292
2,329
2,679
11,694
11,507
  Total Expenditure
11,245
15,830
9,125
63,618
54,900
3 Profit/Loss from Operation Before Other Income (1-2)
471
666
557
2,402
2,124
4 Other Income/(Loss)
159
55
45
369
222
5 Profit/Loss before Interest & Exceptional items (3+4)
630
721
602
2,771
2,346
6 Interest
569
526
395
1,893
1,561
7 Profit/Loss after Interest but before exceptional items (5-6)
61
195
207
878
785
8 Exceptional items 
-
-
-
-
-
9 Profit/Loss before Tax (7-8)
61
195
207
878
785
10 Tax Expenses (Provision for Taxation):      Current tax
-
-
-
158
134
    Deffered tax
-
-
-
-384
-78
     
 
11 Net Profit/Loss after Tax (9-10)
61
195
207
1,104
729
12 Paid up Equity Share Capital (Face Value 10/- Per Share)
354,35
354,35
354,35
354,35
354,35
[Net of allotment money in arrears]
13 Reserves Excluding Revaluation Reserves 
-
-
-
7,630
6,526
14 Earning per share (EPS) before extraordinary item (not Annualised)
-
-
-
-
-
  Basic & Diluted
-
-
-
0.24
0.16
PART-II A. PARTICULARS  OF SHAREHOLDING 
 
1 Public Shareholding
 
  i) Number of Shares
29,02,900
29,02,900
29,02,900
29,02,900
29,02,900
  ii) Percentage of shareholding
63.51%
63.51%
63.51%
63.51%
63.51%
2 Promoters and promoter group Shareholding 
 
a) Pledged/Encumbered
 
i) Number of shares
-
-
-
-
-
  ii) Percentage of shares (as a % of the total shareholding of
-
-
-
-
-
  promoter and promoter group)
 
  iii) Percentage of shares (as a% of the total share capital of the company)
-
-
-
-
-
  b) Non-encumbered
 
i) Number of Shares
1668100
1668100
1668100
1668100
1668100
  ii) Percentage of shares (as a% of the total shareholding
36.49%
36.49%
36.49%
36.49%
36.49%
  of promoter and promoter group)
 
  iii) Percentage of shares (as a % of the total share capital of the company)
100%
100%
100%
100%
100%
 
  B. INVESTORS COMPLAINTS 3 Months ended 31.03.2012
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

STATEMENT OF ASSETS AND LIAB ILITIES (Rupees in '000')
Particulars As at 31.03.2012 As at 31.03.2011
(Audited) (Audited)
A   EQUITY AND LIABILITIES  
1   SHARE HOLDERS FUND  
  a)  Share Capital 35,435 35,435
  b)   Reserves and Surplus 26,350 24,846
    Sub-Total of Shareholders Fund 61,785 60,281
2   NON CURRENT LIABILITIES  
  a) Long term borrowing  23,918 28,467
  b) Deffered tax liability( net) 3,100 3,484
  c) Other  long term liability 98 75
  d) Long term Provision - -
    Sub-Total of Non Current Liabilities 27,116 32,026
3   CURRENT LIABILITIES  
  a) Short term borrowing  - -
  b) Trade payable 9,217 6,630
  c) Other current liabilities 4,057 3,037
  d) Short term provision - -
    Sub-Total of Current Liabilities 13,274 9,667
       
    Total ( 1+2+3) 1,02,175 1,01,974
 
B   ASSETS  
1   NON CURRENT ASSETS  
  a) Fixed Assets 42,361 44,131
  b) Non current investments 3,159 3,159
  c) Long term loans and advances  13,763 13,959
  d) Other Non current assets 525 -
    Sub-Total of Non Current Assets 59,808 61,249
2   CURRENT ASSETS  
  a) Inventories 21,333 19,028
  b) Trade receivable 10,843 9,232
  c) Cash and cash equivalents 9,258 11,714
  d) Short term loans and advances 933 751
    Sub-Total of  Current Assets 42,367 40,725
       
    Total ( 1+2 ) 1,02,175 1,01,974

 

NOTES :-
  1. The above financial results have been taken on record at a meeting of Board of Directors held on  31.05.2012
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures  have been regrouped wherever  required.

 

  For and on behalf of the Board
  COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.05.2012 Chairman & Managing Director.

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in